ProMIS Neurosciences Inc. Common Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for PMN, updated each market day.
PMN AI Sentiment
AI predicts ProMIS Neurosciences Inc. Common Shares stock is likely to increase over the next 10 market days.
Prediction date: Sept. 21, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About ProMIS Neurosciences Inc. Common Shares
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
Sector
Exchange
Market Cap
$120,705,147
Cap Tier
Employees
11
Headquarters
TORONTO, A6
Listed Since
Sept. 30, 2005
PMN Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
PMN Volatility
ProMIS Neurosciences Inc. Common Shares has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
